AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05183841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
Study NCT05346484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-hNIS
Description: CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
Study NCT05346484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
Study NCT06540599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic
Description: comparing the effectiveness of analgesics in endometrial biopsy
Study NCT04748354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: An individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist
Study NCT04748354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Clinical care provided by a geriatrician.
Study NCT04748354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Clinical care provided by a geriatrician.
Study NCT04941300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mailed FIT Outreach
Description: We will mail an introductory letter to eligible individuals describing the importance of CRC screening and noting that follow-up mail will include a FIT Kit. Two weeks later they will receive a packet via mail containing the FIT kit, a one-page invitation inviting FIT completion and FIT instructions, COVID-19 messaging, and a postage-paid envelope for return.
Study NCT04941300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized navigation
Description: The standardized navigation includes, but is not limited to, the following key components:~1. Identification of individuals with abnormal FIT~2. Results review and colonoscopy order by provider~3. Results reporting to patient~4. Insurance approval for colonoscopy~5. Colonoscopy scheduling~6. Bowel preparation \& colonoscopy completion~7. Colonoscopy results provided to patient and CHC~8. Referral-to-Care for patients with CRC (if necessary)
Study NCT05727592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Althernanthera Sissoo
Description: 15g of Althernanthera Sissoo consumed with lunch or dinner per day.
Study NCT05727592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Consultation
Description: Dietary consultation to improve the intakes of vegetables daily
Study NCT06542211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention plan for improving ankle dorsiflexion limitation group (experimental group)
Description: The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
Study NCT06542211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plantar fasciitis routine rehabilitation group
Description: The experimental group received intervention and rehabilitation training directly for the limited ankle dorsiflexion function, which mainly included subtalar joint loosening (increasing the joint activity space), plantar flexor muscle group relaxation (releasing the tension of antagonist muscles), ankle dorsiflexor muscle strengthening (enhancing the strength of agonist muscles), and integrated exercises (integrating ankle dorsiflexion function into gait training).
Study NCT04794400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen mask
Description: All patients fulfilling inclusion criteria would be offered to test the intervention as part of their care. The intervention consisted only of a standardised way to evaluate this new clinical routine.
Study NCT04514328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral 18F-FDG PET-CT
Description: cerebral 18F-FDG PET-CT exam after walking in the garden while 2 weeks (75 minutes/per day from Monday to Friday)
Study NCT04745325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMAART Canada smartphone app
Description: a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
Study NCT04745325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMAART Canada smartphone app
Description: a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazardous fashion
Study NCT06282666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Before the beginning of surgery, all patients will be anesthetized with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 1.5 - 2.5 mL solution. A pencil point spinal needle will be used.
Study NCT06282666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar erector spinae plane block
Description: Investigators will perform the lumbar ESPB under ultrasound control at the L3 level on the ipsilateral site of the surgery. After dissection with 0.9 NaCl, we will leave a catheter in the ESP. Then, we used 0.25% bupivacaine with epinephrine (5mcg/mL), 0.4 mL per kg, up to 40 mL.
Study NCT06282666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Description: After identifying the epidural space and spinal anesthesia (combined technique), a catheter will be placed in the epidural space. Investigators will give an epidural catheter a test dose of 2% lidocaine (2 mL). At the end of the surgery, the patient will receive 5 mL of a mixture containing 0.1% bupivacaine with fentanyl (2 mcg/mL).
Study NCT06282666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient-controlled analgesia
Description: Each participant will receive a pump with oxycodone (1mg/ml) using a patient-controlled analgesia (PCA) technique, a bolus of 1 mL, and a lockout of 5 minutes for the first postoperative day.
Study NCT06282666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed Up and Go test
Description: Investigators will measure the time the patient took to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while rotating 180 degrees. We will assess the patient before the surgery and 24 and 48 hours after hip replacement.
Study NCT06282666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: neuropathic pain symptom inventory
Description: The Neuropathic Pain Symptom Inventory (0-100; 0 denotes no pain, 100 the most severe pain) will be evaluated before the surgery and three and six months following the procedure.
Study NCT05129592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coherent corrective messages
Description: Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
Study NCT05129592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherent corrective messages
Description: Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
Study NCT05871281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Description: Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
Study NCT06282666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lovett test
Description: A physiotherapist will use the six-grade Lovett scale to measure muscle strength, in which 0 denotes no muscle contractility, and 5 denotes the complete range of motion against gravity, with full resistance. We will test this before the surgery, 24 and 48 hours after the operation.
Study NCT05871281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
Study NCT05821933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC108
Description: RC108 plus Furmonertinib and/or Toripalimab
Study NCT05602168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental:Acute leukemia/myelodysplastic or myeloproliferative disease
Description: blood sampling, bone marrow aspirate and buccal swab
Study NCT05232383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polychromatic light
Description: Application of polychromatic light at different times of day
Study NCT05232383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polychromatic light
Description: Application of polychromatic light for 2h30 at different times of day with sleep
Study NCT05232383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red light
Description: Application of red light at different times of day
Study NCT05232383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red light
Description: Application of red light at different times of day with sleep
Study NCT05232383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: green light
Description: Application of green light at different times of day
Study NCT05232383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: green light
Description: Application of green light at different times of day with sleep
Study NCT04958434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST005
Description: TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
Study NCT06187155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INR self-management
Description: will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
Study NCT05256355 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: musculoskeletal ultrasound
Description: The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
Study NCT06282666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual analog scale
Description: Investigators will measure pain intensity with VAS (0-10; 0 denotes no pain, 10 maximal pain) before and after the surgery. Pain will be evaluated at rest and upon the activity.
Study NCT06282666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quality of Recovery 40
Description: Investigators will assess the quality of recovery with QoR-40 a day after the surgery, a month, and three months following the procedure. The minimal score is 40, and the maximal is 200. The higher the result, the better the quality of recovery is.
Study NCT06282666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ability to sit, stand upright, and walk
Description: A physiotherapist will evaluate the patient's ability to sit, stand upright, and walk at planned times.
Study NCT05160727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg ivgtt d1 q3w
Study NCT05160727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Concurrent Chemoradiotherapy:~Irinotecan: 80mg/m2/w (UGT1A1\*28 and \*6: 6/6+GG) or 65mg/m2/w (UGT1A1\*28 and \*6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1\*28 and \*6: 7/7+GG or 6/6+AA or 6/7+GA) Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w.
Study NCT05160727 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy
Study NCT05806762 — intervention group
Intervention type: DEVICE
Intervention: BioIntellisense
Description: Enrolled patients will have a Fitbit placed on their wrist. There is no comparator group enrolled.
Study NCT04393701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional blood sampling
Description: Additional blood sampling on blotting paper will be done in neonates in Normandy, France, compared to National neonatal screening program
Study NCT06164912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Simulation with Pseudofeedback
Description: Participants will receive TMS with bogus feedback that will be displayed on a screen as they imagine movement.
Study NCT06164912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Simulation with Neurofeedback
Description: Participants will receive TMS with live Neurofeedback that will be displayed on a screen for them as they are imagining movement
Study NCT04985942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily.
Study NCT04985942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily.
Study NCT04922788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nanocovax
Description: Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
Study NCT04922788 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,5 mg Aluminum adjuvant
Study NCT05478486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSP008-22
Description: It is single group assignment interventional model in this clinical trial, consisting of 5 cohorts of 3 patients in each, to be enrolled such that there exists an overall gender balance for the entire trial and to also ensure including minimum five (5) patients of TNBC and minimum five (5) male patients.~The trial will be initiated with dosing of a cohort of 03 patient with the Safe starting dose for MSP008-22. Dosing of the patients for the next higher dose cohort will initiate only after: (i) All 03 patients have been recruited in the lower dose Cohort and if a repeat Cohort at this dose level is recommended, another 03 patients have been recruited at same dose level (ii) all dosed patients have completed the allocated study cohort duration, (iii) safety and pharmacokinetic results have been reviewed by the Independent Dose Escalation Committee (DEC) and approved for dose escalation to next cohort.
Study NCT06169917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Resonance Frequency Breathing
Description: Participants are required to pace their breathing to their pre-determined individual resonance frequency.
Study NCT06169917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Breathing at Natural Frequency
Description: Participants are required to pace their breathing to their pre-determined individual breathing frequency at rest.
Study NCT06169917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Stimulations
Description: Participants will undergo a heat stimulation procedure on their left and right foot (the order of which is counterbalanced across participants). During this procedure, there are 10 blocks, with an inter-stimulus interval of 30 seconds between two blocks. During a block, six 6-second heat stimulations (48 degrees) are given. Between the stimulations, the temperature quickly returns to baseline (32 degrees).
Study NCT04827199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Urinary Sphincter implantation
Description: Device preparation (recharge, settings, pairing) Patient preparation Calibration procedure (to verify the device is in full working prior to implantation)~Implantation procedure which includes:~* Perineal approach and bulbar urethral dissection~* Inguinal approach~* Cuff implantation around the urethra~* Transmission cable passing~* Surgery test procedure~* Implantation of the Control Unit~* Closure of the inguinal incision~* Closure of the perineal incision~* Implant disabled mode activation
Study NCT05818449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DigiNet intervention
Description: Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions:~* broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer~* regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians~* monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression~* incorporation of PROs into treatment by physicians~* treatment monitoring and counseling in the case of critical conditions by expert committee
Study NCT06387043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercises with Virtual Reality Glasses
Description: Balance exercises with Virtual Reality Glasses
Study NCT06387043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Exercises with Stroboscopic Glasses
Description: Balance Exercises with Stroboscopic Glasses
Study NCT06387043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Exercises with Visual-Based Metaphor Training
Description: Balance Exercises with Visual-Based Metaphor Training
Study NCT06387043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Balance Exercises
Description: Traditional Balance Exercises
Study NCT05903274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSP191
Description: Subjects will receive intravenous JSP191
Study NCT06568185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA
Description: BIONERV® s the first combination of alpha lipoic acid 300mg and vitamin B complex. Bionerv® is in oral film-coated, orange colour, oblong shape and no marking and embossing on the tablet. Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg. To be taken after meal 1 tablet once daily.
Study NCT06500039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Psychological Intervention Program
Description: An intervention method consisting of three good things in life and gratitude activities was determined for the intervention group. It will take four weeks. Three good deeds will be held for two weeks, and gratitude activities will be held for the last two weeks. Participants will record the interventions on a prepared booklet.
Study NCT06500039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing Daily Routines
Description: An activity was planned for the control group participants to write their daily routines. They will write down their sleep, nutrition, hygiene and shopping routines, which will be different each week for four weeks. Control group participants will also be given a booklet to write on.
Study NCT04977817 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Similac Probiotic Tri-Blend
Description: Probiotic dietary supplement, Similac Probiotic Tri-Blend
Study NCT04767542 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous Infusion
Description: analgesic
Study NCT04767542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: Local anesthetic agent (Bupivacaine 0.5%) will be injected bilaterally to transverses abdominis muscle
Study NCT04784845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N. lactamica Y92-1009
Description: Lyophilised N. lactamica reconstituted in phosphate-buffered saline
Study NCT05683340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180mg of ETC-1002(bempedoic acid)
Description: 180mg, tablet, once daily, for 12 weeks
Study NCT05683340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, tablet, once daily, for 12 weeks
Study NCT05651477 — intervention group
Intervention type: DEVICE
Intervention: Wearable Device (Smart Watch)
Description: A smart watch refers to an embedded system portable watch equipped with improved functions than a general watch, and is almost always in the form of a wrist watch. The device we are using is the Samsung Galaxy 4 (SM-R860/870).
Study NCT05651477 — intervention group
Intervention type: DEVICE
Intervention: Edge-Box
Description: Edge-Box collects data such as air. The device we are using is the TDS Mfepc-4C2R.
Study NCT05238298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.